Outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus efavirenz-based regimens in central China: a real-world assessment.

Author: Yongquan PENG ¹ ; Xujian CAO ¹ ; Yating WANG ¹ ; Weiwei YU ² ; Ziwei ZENG ² ; Min WANG ²
Author Information

1. Graduate Collaborative Training Base of the First Hospital of Changsha, University of South China, Hengyang, Hunan 421001, China.
2. Institute of HIV/AIDS, First Hospital of Changsha, Changsha, Hunan 410000, China.
Publication Type:Letter
MeSH: Humans; Tenofovir/therapeutic use*; Emtricitabine/therapeutic use*; HIV Infections/drug therapy*; Anti-HIV Agents/therapeutic use*
From: Chinese Medical Journal 2023;136(22):2738-2740
CountryChina
Language:English